Attached files
| file | filename |
|---|---|
| EX-99.1 - ERBA Diagnostics, Inc. | v209079_ex99-1.htm |
|
|
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report
January 26,
2011
(Date of
earliest event reported)
IVAX Diagnostics,
Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
1-14798
|
11-3500746
|
||
|
(State
or other jurisdiction of
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
||
|
incorporation
or organization)
|
||||
|
2140
North Miami Avenue
Miami,
Florida
|
33127
|
|||
|
(Address
of principal executive offices)
|
(Zip
Code)
|
(305)
324-2300
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 8.01 Other Events.
On January 26, 2011, IVAX Diagnostics,
Inc. (the “Company”) issued a press release announcing that it has received
clearance from the United States Food and Drug Administration on the 510(k)
premarket submission that the Company had filed for the Mago® 4S, the Company’s
next-generation fully-automated Enzyme-linked Immunosorbent Assay (ELISA) and
Immunofluorescence Assay (IFA) instrumentation system for autoimmune and
infectious disease testing. A copy of the press release is attached
to this Current Report on Form 8-K as Exhibit 99.1.
Item
9.01 Financial Statements and Exhibits.
|
|
(d)
|
Exhibit
99.1 – Press Release dated January 26,
2011
|
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.
|
IVAX
DIAGNOSTICS, INC.
|
||
|
Dated: January
26, 2011
|
By:
|
/s/ Arthur R. Levine
|
|
Arthur
R. Levine
|
||
|
Chief
Financial Officer
|
||
EXHIBIT
INDEX
|
Exhibit
|
Description
|
|
|
99.1
|
Press
Release dated January 26, 2011
|